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ABSTRACT
Background
Chronic lung disease (CLD) occurs frequently in preterm infants. Bronchodilators have the potential effect of dilating small airways with
muscle hypertrophy. Increased compliance and tidal volume and decreased pulmonary resistance have been documented with the use of
bronchodilators in infants with CLD. Therefore, bronchodilators might have a role in the prevention and treatment of CLD.
Objectives
To determine the effect of bronchodilators given as prophylaxis or as treatment for CLD on mortality and other complications of preterm
birth in infants at risk for or identified as having CLD.
Search methods
On 2016 March 7, we used the standard strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of
Controlled Trials (CENTRAL; 2016, Issue 2), MEDLINE (from 1966), Embase (from 1980) and the Cumulative Index to Nursing and Allied
Health Literature (CINAHL; from 1982). We searched clinical trials databases, conference proceedings and the reference lists of retrieved
articles for randomised controlled trials and quasi-randomised trials. We applied no language restrictions.
Selection criteria
Randomised and quasi-randomised controlled trials involving preterm infants were eligible for inclusion. Initiation of bronchodilator
therapy for prevention of CLD had to occur within two weeks of birth. Treatment of patients with CLD had to be initiated before discharge
from the neonatal unit. The intervention had to include administration of a bronchodilator by nebulisation, by metered dose inhaler (with
or without a spacer device) or by intravenous or oral administration versus placebo or no intervention. Eligible studies had to include
at least one of the following predefined clinical outcomes: mortality, CLD, number of days on oxygen, number of days on ventilator,
patent ductus arteriosus (PDA), pulmonary interstitial emphysema (PIE), pneumothorax, intraventricular haemorrhage (IVH) of any grade,
necrotising enterocolitis (NEC), sepsis and adverse effects of bronchodilators.
Data collection and analysis
We used the standard method described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two review
authors extracted and assessed all data provided by each study. We reported risk ratio (RR), risk difference (RD) and number needed to
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treat for an additional beneficial outcome (NNTB) with 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD)
for continuous data. We assessed the quality of the evidence by using the GRADE approach.
Main results
For this update, we identified one new randomised controlled trial investigating effects of bronchodilators in preterm infants. This study,
which enrolled 73 infants but reported on 52 infants, examined prevention of CLD with the use of aminophylline. According to GRADE,
the quality of the evidence was very low. One previously included study enrolled 173 infants to look at prevention of CLD with the use of
salbutamol. According to GRADE, the quality of the evidence was moderate. We found no eligible trial that studied the use of bronchodilator
therapy for treatment of individuals with CLD. Prophylaxis with salbutamol led to no statistically significant differences in mortality (RR
1.08, 95% CI 0.50 to 2.31; RD 0.01, 95% CI -0.09 to 0.11) nor in CLD (RR 1.03, 95% CI 0.78 to 1.37; RD 0.02, 95% CI -0.13 to 0.17). Results
showed no statistically significant differences in other complications associated with CLD nor in preterm birth. Investigators in this study
did not comment on side effects due to salbutamol. Prophylaxis with aminophylline led to a significant reduction in CLD at 28 days of life
(RR 0.18, 95% CI 0.04 to 0.74; RD -0.35, 95% CI -0.56 to -0.13; NNTB 3, 95% CI 2 to 8) and no significant difference in mortality (RR 3.0, 95% CI
0.33 to 26.99; RD 0.08, 95% CI -0.07 to 0.22), along with a significantly shorter dependency on supplementary oxygen in the aminophylline
group compared with the no treatment group (MD -17.75 days, 95% CI -27.56 to -7.94). Tests for heterogeneity were not applicable for any
of the analyses, as each meta-analysis included only one study.
Authors' conclusions
Data are insufficient for reliable assessment of the use of salbutamol for prevention of CLD. One trial of poor quality reported a reduction in
the incidence of CLD and shorter duration of supplementary oxygen with prophylactic aminophylline, but these results must be interpreted
with caution. Additional clinical trials are necessary to assess the role of bronchodilator agents in prophylaxis or treatment of CLD.
Researchers studying the effects of bronchodilators in preterm infants should include relevant clinical outcomes in addition to pulmonary
mechanical outcomes. We identified no trials that studied the use of bronchodilator therapy for treatment of CLD.

PLAIN LANGUAGE SUMMARY
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants
Review question: What are the effects of bronchodilators on mortality and other complications of preterm birth in infants at risk for or
having chronic lung disease (CLD)?
Background: Chronic lung disease is common in babies born before 34 weeks' gestation. Bronchodilators are drugs that cause widening
of the air passages in the lungs. They have been used for chronic lung disease because of their potential effect of dilating small airways
in babies born preterm. Bronchodilators can be inhaled, taken by mouth (a puffer) or injection or received through a nebuliser with a
pressurised aerosol.
Study characteristics: We included randomised and quasi-randomised trials. We included in the analyses two studies that reported on
225 infants.
Study funding resources: We did not identify funding by industry for any trials.
Key results: This review of trials found too little evidence to show positive or negative effects of bronchodilators for prevention of chronic
lung disease. More research is needed. We found no trials that studied the use of bronchodilator therapy for treatment of CLD.
Quality of evidence: The quality of the evidence was moderate for one included trial and low for the other.
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Salbutamol compared with placebo for prevention of CLD
Patient or population: preterm infants at risk of having CLD
Settings: hospital
Intervention: salbutamol
Comparison: placebo
Outcomes

Mortality

Illustrative comparative risks*
(95% CI)
Assumed risk

Corresponding
risk

Placebo

Salbutamol

High-risk population
138 per 1000

128 per 1000

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 1.08
(95% CI 0.50
to 2.31)

173 infants
(1 study)

⊕⊕⊝⊝

Bias: no concerns about allocation concealment and
performance bias in this single study (Denjean 1998)

low

Trusted evidence.
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SUMMARY OF FINDINGS

Consistency: N/A as only 1 study
Precision: serious lack of precision due to small sample
size
Indirectness: study conducted in the target population

CLD at 28 days

High-risk population
523 per 1000

173 infants
(1 study)

⊕⊕⊕⊝
moderate

Bias: no concerns about allocation concealment and
performance bias in this single study (Denjean 1998)
Consistency: N/A as only 1 study
Precision: lack of precision due to small sample size
Indirectness: study conducted in the target population

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based
on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI).
CI: confidence interval; N/A: not applicable; RR: risk ratio.
GRADE Working Group grades of evidence
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High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Aminophylline compared with no intervention for prevention of CLD
Patient or population: preterm infants at risk of developing CLD
Settings: hospital
Intervention: aminophylline
Comparison: no intervention
Outcomes

Mortality

Illustrative comparative risks*
(95% CI)
Assumed risk

Corresponding
risk

No intervention

Aminophylline

High-risk population
115 per 1000

39 per 1000

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 3.0
(95% CI 0.33
to 26.99)

52 infants
(1 study)

⊕⊝⊝⊝
very low

Bias: serious concerns about allocation concealment
and performance bias in this single quasi-randomised
controlled trial (Denjean 1998)
Consistency: N/A as only 1 study

Indirectness: study conducted in the target population
CLD at 28 days

High-risk population
77 per 1000

423 per 1000

RR 0.18
(95% CI 0.04
to 0.74)

52 infants
(1 study)

⊕⊝⊝⊝
very low

Bias: serious concerns about allocation concealment
and performance bias in this single quasi-randomised
controlled trial (Denjean 1998)
Consistency: N/A as only 1 study
Precision: lack of precision due to small sample size
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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CI: confidence interval; N/A: not applicable; RR: risk ratio.

Library

Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Indirectness: study conducted in the target population

Cochrane Database of Systematic Reviews

5

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

BACKGROUND
Description of the condition
Chronic lung disease (CLD), defined as oxygen dependency at 28
days of life or at 36 weeks' postmenstrual age with compatible chest
x-rays, is a pulmonary disorder that occurs frequently in preterm
infants (Northway 1967; Shennan 1988). It is the consequence of
unresolved or abnormally repaired lung damage, and its multifactorial aetiology has been detailed extensively by previous
authors. This includes exposure to high oxygen concentration,
volume-derived trauma, barotrauma, sepsis and inflammation
(Avery 1987; Paita 1991; Rojas 1995). Over past decades, the
survival rate of very low birth weight infants has increased, and
the prevalence of CLD remains high (Parker 1992). Incidence
varies depending on the population studied, the diagnostic criteria
used and variations between clinical management approaches
reported at study centres (O'Brodovich 1985; Avery 1987; Shennan
1988; Hack 1991; Lee 2000). CLD may be associated with chronic
respiratory difficulties, prolonged and recurrent hospitalisation,
growth restriction and death (O'Brodovich 1985; Lee 2000).
Administration of antenatal corticosteroids to mothers likely to
give birth preterm reduces neonatal mortality and the incidence
of respiratory distress syndrome (RDS) but does not reduce the
incidence of CLD (Crowley 2001). Administration of prophylactic
natural surfactant extract does not reduce the incidence of CLD but
reduces the combined outcome of death or CLD (Soll 2001).

Description of the intervention
Bronchodilators may be delivered orally, intravenously or by
nebuliser or pressurised aerosol with or without a spacer device.
With nebulisation or aerosol, only 0.22% to 1.3% of the dose
will reach the lungs (Grigg 1992; Fok 1996). Aerosol tends to be
deposited in the central lung region rather than at the periphery
(Fok 1996). Humidification of the gas reduces lower respiratory
tract deposition of aerosol (Diot 1995). Addition of a spacer
device between the nebuliser and the endotracheal tube (Harvey
1995) and synchronising nebulisation with inspiratory airflow (Diot
1995) increase deposition. Variability in lung deposition among
individuals has been considerable (Fok 1996). All of these factors
serve to modify therapeutic effects.
Numerous bronchodilators are available. Inhaled bronchodilators
include non-specific beta-adrenergic agents, such as isoproterenol
and isoetharine, and specific beta-adrenergic agents, such as
albuterol, metaproterenol, terbutaline and isoetharine. Side effects
of beta agonists include hypokalaemia, tachycardia, cardiac
arrhythmia, tremor, hypertension and hyperglycaemia (Davis
1990; Farrell 1997; Sweet 2000). Inhaled anticholinergic agents
include atropine and ipratropium. Atropine results in more side
effects when compared with ipratropium, as the latter is poorly
absorbed. Side effects of inhaled anticholinergic agents include
tachycardia, decreased gastrointestinal motility, tremor and drying
of respiratory secretions (Davis 1990). Systemic bronchodilators
include the methylxanthines - caffeine and theophylline - which act
by blockage of adenosine receptors. Reported side effects include
vomiting, diarrhoea, tachycardia, hypertension and agitation
(Davis 1990; Farrell 1997; Sweet 2000).

How the intervention might work
Use of bronchodilators in CLD has been justified by their potential
effect of dilating small airways that have muscular hypertrophy.

Cochrane Database of Systematic Reviews

Increased compliance and tidal volume and decreased pulmonary
resistance have been documented when bronchodilators were
used in short-term studies of pulmonary mechanics in infants
with CLD (Sosulski 1982; Cabal 1987; Brudno 1989; Kirpalani 1990;
Pfenninger 1993; Gappa 1997; Fok 1998b).

Why it is important to do this review
This review, titled "Bronchodilators for the prevention and
treatment of CLD in preterm infants", updates a previously
published review in the Cochrane Database of Systematic Reviews
(Ng 2012). We are aware of no other reviews on this topic.

OBJECTIVES
To determine the effect of bronchodilators given as prophylaxis
or as treatment for CLD on mortality and other complications of
preterm birth in infants at risk for or identified as having CLD.

METHODS
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled clinical trials.
Types of participants
Preterm infants (< 37 weeks' gestational age (GA)) at risk for or
identified as having CLD.
Types of interventions
The intervention had to include randomised or quasirandomised administration of a bronchodilator by nebulisation,
by spacer device, intravenously or orally versus placebo
or no intervention. Bronchodilators include albuterol,
aminophylline, atropine, caffeine, clenbuterol, cromakalim,
ephedrine, epinephrine, fenoterol, hexoprenaline, ipratropium,
isoetharine, isoproterenol, orciprenaline, procaterol, terbutaline,
theophylline and tretoquinol. For prevention of CLD, treatment had
to be initiated during the first two weeks of life and had to be
provided for more than seven days. For treatment of CLD, infants
had to receive treatment for more than seven days. Treatment had
to be initiated before discharge from the neonatal unit.
Types of outcome measures
Primary outcomes
For prophylaxis of CLD

Primary outcomes were mortality within the study period and CLD
(defined as oxygen dependency at 28 days of life or at 36 weeks'
postmenstrual age with compatible chest x-ray signs).
For treatment of CLD

Primary outcome was mortality within the study period.
Secondary outcomes
For prophylaxis of CLD

Secondary outcomes were number of days on oxygen, number
of days on ventilator, patent ductus arteriosus (PDA), pulmonary
interstitial emphysema (PIE), pneumothorax, intraventricular
haemorrhage (IVH) of any grade, necrotising enterocolitis (NEC),
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sepsis and adverse effects of bronchodilators. Adverse effects
of bronchodilators included hypokalaemia, tachycardia, cardiac
arrhythmia, tremor, hypertension and hyperglycaemia.
For treatment of CLD

Secondary outcomes were number of days on oxygen, number of
days on ventilator, PDA, PIE, pneumothorax, IVH of any grade, NEC,
sepsis and adverse effects of bronchodilators.

Search methods for identification of studies
See Cochrane Review Group search strategy. Standard search
methods of the Cochrane Neonatal Review Group were employed
(http://neonatal.cochrane.org/; Overview of Searching Databases
for Randomised Trials in Neonatology).

Cochrane Database of Systematic Reviews

For the CINAHL search, we used the following MeSH
terms: bronchopulmonary dysplasia, chronic disease, lung
diseases, adrenergic agents, anticholinergic agents, bronchodilator
agents. We used the following text words: albuterol,
aminophylline, atropine, clenbuterol, cromakalim, ephedrine,
epinephrine, fenoterol, hexoprenaline, ipratropium, isoetharine,
isoproterenol, orciprenaline, procaterol, terbutaline, theophylline
and tretoquinol. We applied the following limits: newborn infant
birth to 1 month.
We updated searches as described above in March 2016. In
addition, we electronically searched abstracts from the Pediatric
Academic Societies' Annual Meetings (2012 to 2015) at PAS
Abstracts2View™ and Web of Science.
Searching other resources

Electronic searches
For the March 2016 update, we used the criteria and standard
methods of Cochrane and the Cochrane Neonatal Review Group
(see the Cochrane Neonatal Group search strategy for specialized
register).
We conducted a comprehensive search that included the Cochrane
Central Register of Controlled Trials (CENTRAL; 2016, Issue 2) in the
Cochrane Library; MEDLINE via PubMed (1996 to 7 March 2016);
Embase (1980 to 2016 March 7); and the Cumulative Index to
Nursing and Allied Health Literature (CINAHL; 1982 to 7 March
2016) using the following search terms: (bronchodilator agents
OR adrenergic agents OR anticholinergic agents OR albuterol OR
aminophylline OR atropine OR clenbuterol OR cromakalim OR
ephedrine OR epinephrine OR fenoterol OR hexoprenaline OR
ipratropium OR isoetharine OR isoproterenol OR orciprenaline OR
procaterol OR terbutaline OR theophylline OR tretoquinol) AND
(bronchopulmonary dysplasia OR lung diseases OR chronic lung
disease OR BPD OR CLD), plus database-specific limiters for RCTs
and neonates (see Appendix 1 for the full search strategies for each
database). We applied no language restrictions.

We searched clinical trials registries for ongoing and recently
completed trials (clinicaltrials.gov; controlled-trials.com; the World
Health Organization International Trials Registry and Platform
(www.whoint/ictrp/search/en/) and the ISRCTN Registry).

Data collection and analysis
We employed standard methods of the Cochrane Neonatal Review
Group and those provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). For Armanian 2014, we
estimated the sample mean and standard deviation from sample
size, median and interquartile range, according to the method used
in Wan 2014.
Selection of studies
We included all randomised and quasi-randomised controlled
trials fulfilling the selection criteria described in the previous
section. Each of two review authors (GN, AO) reviewed the search
results and separately selected studies for inclusion. We resolved
differences by discussion.
Data extraction and management

For the MEDLINE search, we used the following medical
subject heading (MeSH) terms: bronchopulmonary dysplasia,
chronic disease, lung diseases, bronchodilator agents, adrenergic
agents, anticholinergic agents, albuterol, aminophylline,
atropine, clenbuterol, cromakalim, ephedrine, epinephrine,
fenoterol, hexoprenaline, ipratropium, isoetharine, isoproterenol,
orciprenaline, procaterol, terbutaline, theophylline and
tretoquinol. We used the following text words: chronic lung disease,
caffeine, salbutamol, terbutaline, albuterol, aminophylline,
atropine, ipratropium, isoetharine and theophylline. We applied
the following limits: newborn infant birth to 1 month, human,
clinical trial, controlled clinical trial, meta-analysis, multicenter
study and randomised controlled trial.
For the Embase search, we used the following MeSH
terms: bronchodilating agent, adrenergic receptor stimulating
agent, albuterol, clenbuterol, fenoterol, salbutamol, terbutaline,
isoetharine, isoproterenol, lung dysplasia, evidence-based
medicine, clinical trial and multicenter study. We used the following
text words: bronchopulmonary dysplasia, clinical trial, RCT, RCTs,
random, meta-analysis, meta analysis, multicenter, newborn,
neonate, neonatal. We applied the following limits: infant to one
year.

Each of two review authors (GN, AO) extracted data separately.
We resolved differences by discussion. For each included trial,
we sought information regarding random sequence generation,
allocation concealment and whether the trial was single centred
or multi-centred. We looked for information on trial participants
including birth weight, gestational age (GA) at birth, postnatal age,
need for mechanical ventilation and sex; information on clinical
outcomes analysed for CLD at 28 days of life, CLD at 36 weeks'
postmenstrual age, overall mortality, IVH, NEC, air leaks, sepsis and
adverse effects ascribed to the drug. We also sought information
on length of hospital stay and days on oxygen or on mechanical
ventilation.
Assessment of risk of bias in included studies
We employed the standard methods of the Cochrane Neonatal
Review Group. Two review authors (GN, AO) independently
assessed the methodological quality of each trial with respect to
random sequence generation, masking of allocation, masking of
intervention, masking of outcome assessment, completeness of
follow-up, selective reporting and other sources of bias. We have
provided this information in the Characteristics of included studies
tables.
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For this 2016 update, we independently assessed risk of bias (low,
high or unclear) of all included trials by using the Cochrane ‘Risk of
bias’ tool (Higgins 2011) for the following domains.
•
•
•
•
•

Selection bias.
Performance bias.
Attrition bias.
Reporting bias.
Any other bias.

We resolved disagreements by discussion. See Appendix 2 for a
detailed description of risk of bias for each domain.
Measures of treatment effect
We performed statistical analyses using Review Manager software
(RevMan 2014). We analysed categorical data using risk ratio
(RR), risk difference (RD) and the number needed to treat for an
additional beneficial outcome (NNTB) or harmful outcome (NNTH).
We analysed continuous data using mean difference (MD) and
reported the 95% confidence interval (CI) for all estimates.
Assessment of heterogeneity
We planned to estimate treatment effects in individual trials and
to examine heterogeneity between trials by inspecting forest plots
and to quantify the impact of heterogeneity by using the I2 statistic.
We would describe heterogeneity according to the following cutoffs
and labels: < 25% none, 25% to 49% low, 50% to 74% moderate,
75%+ high.
If we detected statistical heterogeneity, we planned to explore
possible causes (e.g. differences in study quality, participants,
intervention regimens or outcome assessments) by performing
post hoc subgroup analyses.
Data synthesis
We used the standard methods of the Cochrane Neonatal Review
Group to synthesise data reported as typical RR, RD if we included
in the analysis data from more than one trial, and NNTB if we
observed a statistically significant reduction in RD and NNTH or
a statistically significant increase in RD. We used weighted mean
difference (WMD) for continuous variables if we included in the
analysis data from more than one trial. We used a fixed-effect model
for meta-analysis.
Quality of evidence
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, as outlined in
the GRADE Handbook (Schünemann 2013), to assess the quality
of evidence for the following (clinically relevant) outcomes: CLD
(defined as oxygen dependency at 28 days of life or at 36
weeks' postmenstrual age with compatible chest x-ray signs)
and mortality within the study period. Secondary outcomes
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were number of days on oxygen, number of days on ventilator,
patent ductus arteriosus (PDA), pulmonary interstitial emphysema
(PIE), pneumothorax, intraventricular haemorrhage (IVH) of
any grade, necrotising enterocolitis (NEC), sepsis and adverse
effects of bronchodilators. Adverse effects of bronchodilators
included hypokalaemia, tachycardia, cardiac arrhythmia, tremor,
hypertension and hyperglycaemia.
Two review authors independently assessed the quality of the
evidence for each of the outcomes above. We considered evidence
from randomised controlled trials as high quality but downgraded
the evidence one level for serious (two levels for very serious)
limitations on the basis of the following: design (risk of bias),
consistency across studies, directness of evidence, precision of
estimates and presence of publication bias. We used the GRADEpro
2014 Guideline Development Tool to create a ‘Summary of findings’
table to report the quality of the evidence.
The GRADE approach yields an assessment of the quality of a body
of evidence and assignment to one of four grades.
• High: We are very confident that the true effect lies close to that
of the estimate of effect.
• Moderate: We are moderately confident in the effect estimate:
The true effect is likely to be close to the estimate of effect but
may be substantially different.
• Low: Our confidence in the effect estimate is limited: The true
effect may be substantially different from the estimate of effect.
• Very low: We have very little confidence in the effect estimate:
The true effect is likely to be substantially different from the
estimate of effect.

RESULTS
Description of studies
Results of the search
Previous searches revealed one study on prevention (Denjean 1998)
and no studies on treatment of CLD. For the update in 2012, review
authors identified four studies assessing pulmonary mechanics
after the use of bronchodilators (Khalaf 2000; Fayon 2007; Ramos
2007; Costa 2009), but none qualified for inclusion in the review (see
table of Characteristics of excluded studies).
For this update in 2016, the search revealed two additional
studies. Armanian 2014 investigated the prophylactic effect of
aminophylline on the incidence of CLD in very preterm infants.
Almaraz 2012 studied effects of inhaled fluticasone 125 µg,
theophylline 1 mg and fluticasone + theophylline and measured
lung liquid interleukin (IL)-1β, IL-6 and tumour necrosis factor
(TNF)-α. This study did not qualify for inclusion (see Characteristics
of excluded studies).
Figure 1 shows the study flow diagram for this review update.
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Figure 1. Study flow diagram: review update.
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Included studies
Denjean 1998, a multi-centre, randomised, double-blind trial,
enrolled 173 infants needing ventilatory support from six neonatal
intensive care units (NICUs) in France.
• Objective: To investigate the potential efficacy of inhaled
beclomethasone, salbutamol or their combination for
preventing CLD in ventilator-dependent preterm neonates.
• Population: Infants with respiratory distress syndrome and
gestational age of less than 31 weeks' PMA were eligible for the
study if they required ventilatory support on the 10th postnatal
day (re-assessed daily between the 7th and 10th days). The
study did not include babies with major malformations, sepsis
or current bronchopulmonary infection and those treated with
corticosteroids or bronchodilators.
• Intervention: Investigators provided interventions to four
treatment groups: placebo + placebo (P + P), placebo +
salbutamol (P + S), placebo + beclomethasone (P + B) and
salbutamol + beclomethasone (S + B). Salbutamol was given at
a dose of 200 micrograms every four hours (1200 micrograms/
d) via metered dose inhaler and spacer device. Beclomethasone
was given at a dose of 250 micrograms via metered dose inhaler
and spacer device. Researchers initiated treatment on the 10th
or 11th postnatal day and continued treatment for 28 days,
tapering the dose off over eight days.
• Outcomes: Primary outcomes were mortality and CLD
characterised at 28 days of life on the basis of clinical
(oxygen dependency) and radiographic criteria. Secondary
outcomes were duration of ventilatory support, duration of
oxygen supplementation, ventilatory index (product of oxygen
tension and mean airway pressure) measured every week
until extubation, pulmonary complications (pneumothorax,
interstitial emphysema), sepsis, mandatory intravenous
corticosteroid treatment according to usual practice at each
centre and episodes of bronchospasm treated with intravenous
bronchodilators. Study authors did not provide data on drug
deposition.
Armanian 2014 enrolled 73 infants and was conducted in the NICU
at Alzahra and Shahid Beheshti Hospitals in Isfahan, Iran, between
March 2012 and April 2013.
• Objective: To assess the safety and preventive effects of
aminophylline in terms of the incidence of CLD in very preterm
infants.
• Population: Infants were born preterm with birth weight of
1200 grams or less. The study did not include infants who had
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major congenital anomalies, asphyxia, occurrence of apnoea
and need for mechanical ventilation in the first 24 hours after
birth, congenital cyanotic heart disease, small for gestational
age intrauterine growth and sepsis in the first 10 days after birth.
• Intervention: For the aminophylline group (A), after
consideration of inclusion and exclusion criteria for the preterm
neonate with birth weight of 1200 grams or less, investigators
began treatment with 5 mg/kg of aminophylline, given as a
loading dose parenterally; this was followed by 1.5 mg/kg given
as a maintenance dose each eight hours for the first 10 days of
life. In the control group (C), after consideration of inclusion and
exclusion criteria for the premature neonate with birth weight of
1200 grams or less, investigators administered no aminophylline
during the first 10 days of life.
• Outcomes: Primary and secondary outcomes included duration
of dependency on oxygen and incidence of CLD. Both groups
made decisions regarding CLD uniformly. Neonates were
considered as having CLD/bronchopulmonary dysplasia (BPD)
if they had been oxygen dependent for at least 28 days after
birth, and if the severity of CLD was judged according to preset
criteria. Aminophylline side effects (tachycardia,hypertension)
and mortality were recorded as other secondary outcomes.
• Note: This was a quasi-randomised trial of 73 infants, 52 of whom
(26 in each group) were analysed.
We identified no trials that studied use of bronchodilator therapy
for treatment of individuals with CLD.
Excluded studies
We rejected the following studies because they addressed only
pulmonary mechanics: Kao 1984; Kao 1987; Wilkie 1987; Kao 1988;
Kao 1989; Rotschild 1989; Stefano 1991; Pfenninger 1993; Lee
1994; Gappa 1997; Nguyen 1997; Fok 1998a and Sivakumar 1999.
We rejected Guimaraes 1993 because it was not a randomised
controlled trial, and infants were given beclomethasone and
salbutamol together. For the 2012 update, we excluded the
following four studies because they addressed only pulmonary
mechanics: Khalaf 2000; Fayon 2007; Ramos 2007; and Costa 2009.
For this 2016 update, we rejected Almaraz 2012 because study
authors presented study findings as an abstract and provided
insufficient information on the study population.

Risk of bias in included studies
We presented information on risk of bias in the included trials in the
Risk of bias graph (Figure 2) and in the Risk of bias summary (Figure
3).
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Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Allocation

Secondary outcomes

We determined that Denjean 1998 had low risk of bias, as the
randomisation process and preparation of therapeutic units were
centralised. Armanian 2014 had high risk of bias regarding random
sequence generation and allocation concealment because in
selecting neonates randomly, investigators assigned neonates with
an even digit at the end of their file numbers to the aminophylline
group and those with file numbers ending in an odd digit to the
control group.

Duration of assisted ventilation (Outcome 1.3)

Blinding
Armanian 2014 had high risk of bias as investigators used no
placebo. Risk was low in Denjean 1998.
Incomplete outcome data
Denjean 1998 originally randomised 178 infants but did not obtain
informed consent for or withdrew five infants, leaving 173 infants
in the trial. Researchers reported results for these 173 infants. We
rated the study as having low risk of attrition bias.
However, Armanian 2014 had high risk of attrition bias; of 73 infants
randomised, we included only 52 in the analyses.
Selective reporting
Protocols for the included studies were not available to us, so we
could not judge whether any deviations occurred.
Other potential sources of bias
We judged Denjean 1998 as having unclear risk of other bias, as
some infants were randomised before consent was obtained.

Results showed no statistically significant difference in the duration
of assisted ventilation (MD -1.63 days, 95% CI -5.63 to 2.37) (Analysis
1.3).
Duration of oxygen supplementation (Outcome 1.4)

Results revealed no statistically significant difference in the
duration of oxygen supplementation (MD -2.82 days, 95% CI -11.91
to 6.27) (Analysis 1.4).
Mean age of weaning from ventilatory support (Outcome 1.5)

Researchers found no statistically significant difference in
weaning from respiratory support (assisted ventilation or oxygen
supplementation) (MD -2.87 days, 95% CI -11.28 to 5.54) (Analysis
1.5).
Need for intravenous dexamethasone (Outcome 01.6)

Investigators found no significant effect (RR 0.77, 95% CI 0.49 to
1.19; RD -0.08, 95% CI -0.22 to 0.05) (Analysis 1.6).
Infants with one or more episodes of infection (Outcomes 1.7 and 1.8)

Results showed no statistically significant effect on respiratory
infection, defined as increasing ventilatory requirements
associated with increased serum C-reactive protein and bacteria
in tracheal aspirates (RR 0.61, 95% CI 0.27 to 1.39; RD -0.06, 95%
CI -0.16 to 0.04) (Analysis 1.7), and no significant effect on sepsis,
defined as a positive blood culture (RR 1.06, 95% CI 0.54 to 2.06; RD
0.01, 95% CI -0.10 to 0.12) (Analysis 1.8).

Salbutamol versus placebo in the prophylaxis of CLD
(Comparison 1)

Study authors stated that they found no differences
in the secondary outcomes of pulmonary complications,
weekly ventilatory index until extubation, interruptions in
randomised treatment for intravenous salbutamol and episodes
of bronchospasm treated with intravenous bronchodilators.
However, they did not present these data and did not comment on
adverse effects associated with salbutamol.

In Denjean 1998, investigators compared results of salbutamol and
placebo groups (n = 173) in terms of the following outcomes.

Aminophylline versus no intervention in the prophylaxis of
CLD (Comparison 2)

(As only one study performed these comparisons, tests for
heterogeneity were not applicable.)

In Armanian 2014, investigators compared results of the
aminophylline and placebo groups (n = 52) for the following
outcomes.

Effects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2

Primary outcomes
Mortality (Outcome 1.1)

(As only one study performed these comparisons, tests for
heterogeneity were not applicable.)

Results showed no significant effect (RR 1.08, 95% CI 0.50 to 2.31;
RD 0.01, 95% CI -0.09 to 0.11) (Analysis 1.1) (low-quality evidence).

Primary outcomes

CLD at 28 days (Outcome 1.2)

For overall (mild, moderate or severe) CLD, results revealed no
significant effect (RR 1.03, 95% CI 0.78 to 1.37; RD 0.02, 95% CI -0.13
to 0.17) (Analysis 1.2) (moderate-quality evidence).

Mortality (Outcome 2.1)

Results showed no significant effect (RR 3.0, 95% CI 0.33 to 26.99;
RD 0.08, 95% CI -0.07 to 0.22) (Analysis 2.1).
CLD at 28 days (Outcome 2.2)

Risk for CLD at 28 days was significantly less in the aminophylline
group than in the no intervention group (RR 0.18, 95% CI 0.04 to
0.74; RD -0.35, 95% CI -0.56 to -0.13; NNTB 3, 95% CI 2 to 8) (Analysis
2.2; Figure 4).
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Figure 4. Forest plot of comparison: 2 Aminophylline versus no intervention in the prophylaxis of CLD, outcome: 2.2
CLD at 28 days.

Secondary outcomes
Duration of dependency on supplementary oxygen (days) (Outcome
2.3)

The mean time of oxygen dependency was significantly shorter in
the aminophylline group than in the no intervention group (MD
-17.75 days, 95% CI -27.56 to -7.94) (Analysis 2.3; Figure 5).

Figure 5. Forest plot of comparison: 2 Aminophylline versus no intervention in the prophylaxis of CLD, outcome: 2.3
Duration of dependency on supplementary oxygen (days).

Side effects (tachycardia, hypertension) (Outcome 2.4)

Investigators noted no side effects among infants included in the
study (RR not estimable; RD 0.08, 95% CI -0.07 to 0.07) (Analysis 2.4).

DISCUSSION
For the update conducted in March 2016, review authors identified
two trials (Armanian 2014; Almaraz 2012). We excluded Almaraz
2012, as the study was published only in abstract format.
Investigators did not report the age of infants at the time of
treatment for severe bronchopulmonary dysplasia. They did report
the following outcomes: decreased fraction of inspired oxygen
(FiO2) > 0.20; lung liquid interleukin (IL)-1β, IL-6 and tumour
necrosis factor (TNF-α).
For the update conducted in April 2012, review authors identified
four trials (Khalaf 2000; Fayon 2007; Ramos 2007; Costa 2009).
However, they excluded these trials as all reported on pulmonary
mechanical outcomes and provided no information on clinical
outcomes of interest for this review. Denjean 1998 examined
prevention of chronic lung disease (CLD). No studies assessed
important clinical outcomes of treatment for CLD. Excluded
studies (Kao 1984; Kao 1987; Wilkie 1987; Kao 1988; Kao 1989;
Rotschild 1989; Stefano 1991; Guimaraes 1993; Pfenninger 1993;
Lee 1994; Gappa 1997; Nguyen 1997; Fok 1998a; Sivakumar 1999)
found short-term decreases in pulmonary resistance and increases
in pulmonary compliance. However, they did not examine our
primary and secondary clinical outcomes.
Denjean 1998 showed no evidence that salbutamol reduced
mortality or CLD at 28 days of life in preterm infants at risk
of developing CLD. This study did not report outcomes for CLD

at 36 weeks' postmenstrual age, which is generally regarded as
the more important outcome with regards to CLD. Study authors
did not demonstrate earlier weaning from respiratory support
with salbutamol and did not report the duration of oxygen
supplementation. Researchers demonstrated that salbutamol does
not affect the need for intravenous dexamethasone or sepsis
compared with placebo. Use of dexamethasone may have varied
between the six neonatal intensive care units (NICUs) involved in
the study. Denjean 1998 did not comment on adverse effects of
salbutamol.
Denjean 1998 found no significant differences in outcomes
upon comparing salbutamol with placebo. Salbutamol showed
no evidence of effect in Denjean 1998; several reasons may
explain this. The study did not assess drug deposition, which
is known to change the therapeutic effect of the drug. The
amount of drug delivered to the lungs varied with the route of
administration. The mode of delivery used may have led to delivery
of insufficient drug to the lungs. The pathophysiology of CLD is
multi-factorial. Mechanisms besides muscle hypertrophy in small
airways may explain why salbutamol showed no evidence of effect
for prevention of CLD.
Armanian 2014 found that aminophylline reduced CLD at 28 days
in preterm infants at risk of developing CLD and reduced the
duration of dependency on supplementary oxygen but found
no differences in mortality. Study authors reported no side
effects of aminophylline. However, this study was of overall poor
methodological quality, and these outcomes should be interpreted
with caution.
Review authors identified no trials that studied use of
bronchodilator therapy for treatment of CLD.
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Summary of main results
Review authors were surprised at the paucity of trials that
assessed clinical outcomes of bronchodilators in CLD. We found
no randomised controlled trials in an extensive search of the
literature on use of bronchodilators in the treatment of CLD. Two
trials assessed the effectiveness of two different bronchodilators
(aminophylline and salbutamol); as interventions differed, we
could not combine study results in meta-analyses. Aminophylline
may have beneficial effects in prevention of CLD, but the poor
quality of the one small included trial prevents application of
findings to clinical practice.

Overall completeness and applicability of evidence
Evidence on the use of bronchodilators for prevention or treatment
of CLD is currently lacking.

Quality of the evidence
According to GRADE, the quality of the evidence varied; Denjean
1998 provided high-quality evidence, and Armanian 2014 provided
evidence of low quality.

Potential biases in the review process
We are aware of no bias in our review process. No review authors
have published studies regarding bronchodilators for prevention
and treatment of CLD.

Agreements and disagreements with other studies or
reviews
We are aware of no other systematic reviews on this topic.

AUTHORS' CONCLUSIONS
Implications for practice
Results of this systematic review show no current evidence for the
use of salbutamol or aminophylline for prevention of CLD. We were
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unable to address the question of whether bronchodilators are
useful in the treatment of CLD. Future use of bronchodilators in
preterm infants should occur in the scenario of placebo-controlled
randomised clinical trials.

Implications for research
In light of the paucity of clinical trials available for inclusion
in this systematic review, future research should be directed
towards addressing the question of whether bronchodilators
have a preventive role in the following: treatment of preterm
infants at risk of CLD to reduce mortality, CLD at 36 weeks'
postmenstrual age, duration of ventilatory support, duration of
oxygen supplementation and long-term outcomes (to 18 months'
corrected gestational age). Future studies should be conducted to
evaluate whether bronchodilators have a role in the treatment of
preterm infants with established CLD to reduce mortality, duration
of ventilatory support or duration of oxygen supplementation. It
is important that researchers assess whether this occurs without
undue side effects, and that they assess clinical outcomes beyond
short-term pulmonary function. A wide variety of bronchodilators
are available, and studies included in this review assessed only
salbutamol and aminophylline. Future research should examine
use of different bronchodilator drugs, different drug dosages and
different modes of delivery, and should assess drug deposition.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Armanian 2014
Methods

• Blinding to randomisation - no; quasi-randomised trial
• Blinding to intervention - no
• Complete follow-up - no; 73 infants were randomised, but only 26 in each group (52) were included in
analyses
• Blinding to outcome - no

Participants

Infants born preterm with at‑birth weight of 1200 grams or less

Interventions

In the aminophylline group (A), after consideration of inclusion and exclusion criteria for the preterm
neonate with weight ≤ 1200 grams, 5 mg/kg of aminophylline was given as a loading dose; this was followed by 1.5 mg/kg, given each 8 hours as a maintenance dose, for the first 10 days of life.
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Outcomes

Duration of oxygen dependency, incidence of CLD

Notes

73 infants were randomised, but only 26 in each group (52) were included in analyses.

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

High risk

To select neonates randomly, investigators assigned neonates with an even
digit at the end of their file numbers to group A, and those with file numbers
ending in an odd digit to group C.

Allocation concealment
(selection bias)

High risk

To select neonates randomly, investigators assigned neonates with an even
digit at the end of their file numbers to group A, and those with file numbers
ending in an odd digit to group C.

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Researchers used no placebo.

Blinding of outcome assessment (detection bias)
All outcomes

High risk

Researchers used no placebo.

Incomplete outcome data
(attrition bias)
All outcomes

High risk

73 infants were randomised, but only 52 were included in analyses. No intention-to-treat analysis

Selective reporting (reporting bias)

Unclear risk

The protocol for this study was not available to us, so we cannot judge
whether deviations from the protocol occurred.

Other bias

Low risk

Study appears free of other bias.

Denjean 1998
Methods

Randomised prospective double-blind placebo-controlled trial
Study location: 6 NICUs in France. Study period: April 1993 to April 1995
• Blinding to randomisation - yes
• Blinding to intervention - yes
• Complete follow-up; originally investigators randomised 178 infants, but they did not obtain informed consent for or withdrew 5 infants, leaving 173 infants in the trial. They provided results for all
173 infants.
• Blinding to outcome - no

Participants

Number of patients entered into the study: 87 in treatment (salbutamol) group and 86 in placebo group
Mean (SD) BW: 1028 grams ± 220 grams in the salbutamol arm; 1071 grams ± 254 grams in the placebo
arm
Mean (SD) GA: 27.7 weeks ± 1.5 weeks in the salbutamol arm; 27.7 weeks ± 1.6 weeks in the placebo
arm
Age at enrolment into the study: day 10 or day 11
Other characteristics: All infants had RDS and GA < 31 weeks and needed ventilatory support on the
10th postnatal day
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Exclusion criteria: major malformations, sepsis, current bronchopulmonary infection, treatment with
corticosteroids or bronchodilators
Interventions

Researchers used metered dose inhalers to administer salbutamol 200 micrograms every 4 hours or
the corresponding placebo. They provided treatment on the 10th or 11th postnatal day and for 28 days,
with dose tapering over a period of 8 days

Outcomes

Primary outcomes were mortality and CLD at 28 days on the basis of oxygen dependency and radiographic criteria. Secondary outcomes were duration of ventilatory support, duration of oxygen supplementation, ventilatory index measured every week until extubation, pulmonary complications
(pneumothorax, interstitial emphysema), mandatory intravenous corticosteroid treatment according
to usual practice at each centre and episodes of bronchospasm treated with intravenous bronchodilators. Results showed no significant differences for any outcomes.

Notes

Incidence of pulmonary complications and episodes of bronchospasm were said to be the same, but
investigators did not present the data. Joseph Beyene assembled data for the 2 main groups - salbutamol and placebo - from subgroup data provided in the original report for the following outcomes: duration of assisted ventilation, duration of oxygen supplementation and age at weaning from respiratory
support.

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomisation was blinded and was stratified by centre, GA and mode of ventilation used at trial entry at 10 days of age (ET IMV or IMV/CPAP) (Denjean
[pers comm]).

Allocation concealment
(selection bias)

Low risk

Randomisation was blinded.

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

Staff was blinded to which drug or placebo was given.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Staff assessed outcomes while blinded to which drug or placebo was given.

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Complete follow-up: Originally, investigators randomised 178 infants, but they
did not obtain informed consent or withdrew 5 infants, leaving 173 infants in
the trial. They reported results for all 173 infants.

Selective reporting (reporting bias)

Unclear risk

The protocol for the study was not available to us, so we cannot judge whether
deviations from the protocol occurred.

Other bias

Unclear risk

Investigators randomised some infants before obtaining consent.

BW: birth weight; CLD: chronic lung disease; CPAP: continuous positive airway pressure; ET: endotracheal; GA: gestational age; IMV: invasive
mechanical ventilation; NICU: neonatal intensive care unit; RDS: respiratory distress syndrome; SD: standard deviation.

Characteristics of excluded studies [ordered by study ID]
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Study

Reason for exclusion

Almaraz 2012

Investigators published study findings in abstract form only. They did not report age of infants at
time of treatment for severe bronchopulmonary dysplasia. They reported the following outcomes:
decreased fraction of inspired oxygen (FiO2) > 0.20; lung liquid interleukin (IL)-1β, IL-6 and tumour
necrosis factor (TNF)-α.

Costa 2009

Researchers reported only pulmonary mechanics.

Fayon 2007

Researchers reported only pulmonary mechanics.

Fok 1998a

Researchers reported only pulmonary mechanics.

Gappa 1997

Researchers reported only pulmonary mechanics.

Guimaraes 1993

Not a randomised controlled trial. Investigators gave infants both beclomethasone and salbutamol
but not separately.

Kao 1984

Not a randomised controlled trial

Kao 1987

Researchers reported only pulmonary mechanics.

Kao 1988

Researchers reported only pulmonary mechanics.

Kao 1989

Cross-over study; infants received placebo, metaproterenol, atropine and metaproterenol plus atropine. Researchers reported only pulmonary mechanics.

Khalaf 2000

This study compared doses of albuterol delivered by metered dose inhaler with spacer and jet nebuliser. It is not clear whether this was a randomised controlled trial or a controlled trial.

Lee 1994

Researchers reported only pulmonary mechanics.

Nguyen 1997

Researchers reported only pulmonary mechanics.

Pfenninger 1993

Researchers reported only pulmonary mechanics.

Ramos 2007

The objective of the study was to assess the effect of salbutamol on pulmonary mechanics of
asymptomatic very low birth weight infants at the moment of discharge from the neonatal intensive care unit. Researchers reported only pulmonary mechanics.

Rotschild 1989

Each participant was his own control and was randomly assigned to a placebo-salbutamol or
salbutamol-placebo sequence. Researchers reported only pulmonary mechanics.

Sivakumar 1999

Researchers reported only pulmonary mechanics.

Stefano 1991

Researchers reported only pulmonary mechanics.

Wilkie 1987

Researchers reported only pulmonary mechanics.

DATA AND ANALYSES
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Comparison 1. Salbutamol versus placebo in the prophylaxis of CLD
Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mortality

1

173

Risk Ratio (M-H, Fixed, 95%
CI)

1.08 [0.50, 2.31]

2 CLD at 28 days

1

173

Risk Ratio (M-H, Fixed, 95%
CI)

1.03 [0.78, 1.37]

3 Duration of assisted ventilation
(days)

1

173

Mean Difference (IV, Fixed,
95% CI)

-1.63 [-5.63, 2.37]

4 Duration of oxygen supplementation (days)

1

173

Mean Difference (IV, Fixed,
95% CI)

-2.82 [-11.91, 6.27]

5 Age of weaning from ventilatory
support (days)

1

173

Mean Difference (IV, Fixed,
95% CI)

-2.87 [-11.28, 5.54]

6 Need for intravenous dexamethasone

1

173

Risk Ratio (M-H, Fixed, 95%
CI)

0.77 [0.49, 1.19]

7 Infants with 1 or more episodes of
respiratory infection

1

173

Risk Ratio (M-H, Fixed, 95%
CI)

0.61 [0.27, 1.39]

8 Infants with 1 or more episodes of
sepsis (positive blood culture)

1

173

Risk Ratio (M-H, Fixed, 95%
CI)

1.06 [0.54, 2.06]

Analysis 1.1. Comparison 1 Salbutamol versus placebo in the prophylaxis of CLD, Outcome 1 Mortality.
Study or subgroup

Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Denjean 1998

Weight

Risk Ratio
M-H, Fixed, 95% CI

12/87

11/86

100%

1.08[0.5,2.31]

87

86

100%

1.08[0.5,2.31]

Total (95% CI)
Total events: 12 (Treatment), 11 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=0.19(P=0.85)

0.5

Favours treatment

0.7

1

1.5

2

Favours control

Analysis 1.2. Comparison 1 Salbutamol versus placebo in the prophylaxis of CLD, Outcome 2 CLD at 28 days.
Study or subgroup

Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Denjean 1998

Total (95% CI)

Weight

Risk Ratio
M-H, Fixed, 95% CI

47/87

45/86

100%

1.03[0.78,1.37]

87

86

100%

1.03[0.78,1.37]

Total events: 47 (Treatment), 45 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=0.22(P=0.82)
Favours treatment

0.5

0.7

1

1.5
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Analysis 1.3. Comparison 1 Salbutamol versus placebo in the
prophylaxis of CLD, Outcome 3 Duration of assisted ventilation (days).
Study or subgroup

Treatment
N

Control

Mean(SD)

Denjean 1998

87

Total ***

87

21.4 (12.4)

N

Mean Difference

Mean(SD)

86

Weight

Mean Difference

Fixed, 95% CI

Fixed, 95% CI

23.1 (14.4)

86

100%

-1.63[-5.63,2.37]

100%

-1.63[-5.63,2.37]

Heterogeneity: Not applicable
Test for overall effect: Z=0.8(P=0.42)
Favours treatment

-10

-5

0

5

10

Favours control

Analysis 1.4. Comparison 1 Salbutamol versus placebo in the prophylaxis
of CLD, Outcome 4 Duration of oxygen supplementation (days).
Study or subgroup

Treatment
N

Control

Mean(SD)

Denjean 1998

87

Total ***

87

30.4 (29.9)

N

Mean Difference

Mean(SD)

86

Weight

Mean Difference

Fixed, 95% CI

Fixed, 95% CI

33.2 (31.1)

86

100%

-2.82[-11.91,6.27]

100%

-2.82[-11.91,6.27]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=0.61(P=0.54)
Favours treatment

-20

-10

0

10

20

Favours control

Analysis 1.5. Comparison 1 Salbutamol versus placebo in the prophylaxis
of CLD, Outcome 5 Age of weaning from ventilatory support (days).
Study or subgroup

Treatment
N

Denjean 1998

87

Total ***

87

Control

Mean(SD)
38.5 (30)

N

Mean Difference

Mean(SD)

86

Weight

Mean Difference

Fixed, 95% CI

Fixed, 95% CI

41.4 (26.4)

86

100%

-2.87[-11.28,5.54]

100%

-2.87[-11.28,5.54]

Heterogeneity: Not applicable
Test for overall effect: Z=0.67(P=0.5)
Favours treatment

-20

-10

0

10

20

Favours control

Analysis 1.6. Comparison 1 Salbutamol versus placebo in the
prophylaxis of CLD, Outcome 6 Need for intravenous dexamethasone.
Study or subgroup

Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Denjean 1998

Total (95% CI)

Weight

Risk Ratio
M-H, Fixed, 95% CI

24/87

31/86

100%

0.77[0.49,1.19]

87

86

100%

0.77[0.49,1.19]

Total events: 24 (Treatment), 31 (Control)
Favours treatment

0.5

0.7

1

1.5

2
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Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Weight

Risk Ratio
M-H, Fixed, 95% CI

Heterogeneity: Not applicable
Test for overall effect: Z=1.19(P=0.24)
Favours treatment

0.5

0.7

1

1.5

2

Favours control

Analysis 1.7. Comparison 1 Salbutamol versus placebo in the prophylaxis
of CLD, Outcome 7 Infants with 1 or more episodes of respiratory infection.
Study or subgroup

Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Denjean 1998

Weight

Risk Ratio
M-H, Fixed, 95% CI

8/87

13/86

100%

0.61[0.27,1.39]

87

86

100%

0.61[0.27,1.39]

Total (95% CI)
Total events: 8 (Treatment), 13 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=1.18(P=0.24)

Favours treatment

0.2

0.5

1

2

5

Favours control

Analysis 1.8. Comparison 1 Salbutamol versus placebo in the prophylaxis of CLD,
Outcome 8 Infants with 1 or more episodes of sepsis (positive blood culture).
Study or subgroup

Treatment

Control

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Denjean 1998

Total (95% CI)

Weight

Risk Ratio
M-H, Fixed, 95% CI

15/87

14/86

100%

1.06[0.54,2.06]

87

86

100%

1.06[0.54,2.06]

Total events: 15 (Treatment), 14 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=0.17(P=0.87)
Favours treatment

0.5

0.7

1

1.5

2

Favours control

Comparison 2. Aminophylline versus no intervention in the prophylaxis of CLD
Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mortality

1

52

Risk Ratio (M-H, Fixed, 95% CI)

3.0 [0.33, 26.99]

2 CLD at 28 days

1

52

Risk Ratio (M-H, Fixed, 95% CI)

0.18 [0.04, 0.74]

3 Duration of dependency of
supplementary oxygen (days)

1

52

Mean Difference (IV, Fixed, 95%
CI)

-17.75 [-27.56,
-7.94]

4 Side effects (tachycardia, hypertension)

1

52

Risk Ratio (M-H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

Cochrane

Trusted evidence.
Informed decisions.
Better health.

Library

Cochrane Database of Systematic Reviews

Analysis 2.1. Comparison 2 Aminophylline versus no intervention in the prophylaxis of CLD, Outcome 1 Mortality.
Study or subgroup

Aminophylline

No intervention

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Weight

Risk Ratio
M-H, Fixed, 95% CI

Armanian 2014

3/26

1/26

100%

3[0.33,26.99]

Total (95% CI)

26

26

100%

3[0.33,26.99]

Total events: 3 (Aminophylline), 1 (No intervention)
Heterogeneity: Not applicable
Test for overall effect: Z=0.98(P=0.33)
Favours [aminophylline]

0.01

0.1

1

10

100

Favours [no intervention]

Analysis 2.2. Comparison 2 Aminophylline versus no
intervention in the prophylaxis of CLD, Outcome 2 CLD at 28 days.
Study or subgroup

Aminophylline

No intervention

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Weight

Risk Ratio
M-H, Fixed, 95% CI

Armanian 2014

2/26

11/26

100%

0.18[0.04,0.74]

Total (95% CI)

26

26

100%

0.18[0.04,0.74]

Total events: 2 (Aminophylline), 11 (No intervention)
Heterogeneity: Not applicable
Test for overall effect: Z=2.38(P=0.02)
Favours [aminophylline]

0.01

0.1

1

10

100

Favours [no intervention]

Analysis 2.3. Comparison 2 Aminophylline versus no intervention in the prophylaxis
of CLD, Outcome 3 Duration of dependency of supplementary oxygen (days).
Study or subgroup

Aminophylline
N

Armanian 2014

26

Total ***

26

No intervention

Mean(SD)

N

6.9 (7.4)

26

Mean Difference

Mean(SD)

Weight

Mean Difference

Fixed, 95% CI

Fixed, 95% CI

24.6 (24.4)

26

100%

-17.75[-27.56,-7.94]

100%

-17.75[-27.56,-7.94]

Heterogeneity: Not applicable
Test for overall effect: Z=3.55(P=0)
Favours [aminophylline]

-100

-50

0

50

100

Favours [no intervention]

Analysis 2.4. Comparison 2 Aminophylline versus no intervention in the
prophylaxis of CLD, Outcome 4 Side effects (tachycardia, hypertension).
Study or subgroup

Aminophylline

No intervention

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Weight

Risk Ratio
M-H, Fixed, 95% CI

Armanian 2014

0/26

0/26

Not estimable

Total (95% CI)

26

26

Not estimable

Total events: 0 (Aminophylline), 0 (No intervention)
Favours [aminophylline]

0.01

0.1

1

10

100
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Aminophylline

No intervention

Risk Ratio

n/N

n/N

M-H, Fixed, 95% CI

Weight

Risk Ratio
M-H, Fixed, 95% CI

Heterogeneity: Not applicable
Test for overall effect: Not applicable
Favours [aminophylline]

0.01

0.1

1

10

100

Favours [no intervention]

APPENDICES
Appendix 1. Standard search methods
PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan*
or neonat*) AND (randomised controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomised [tiab] OR placebo
[tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))
Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW
or Newborn or infan* or neonat*) AND (human not animal) AND (randomised controlled trial or controlled clinical trial or randomised or
placebo or clinical trials as topic or randomly or trial or clinical trial)
CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan*
or neonat*) AND (randomised controlled trial OR controlled clinical trial OR randomised OR placebo OR clinical trials as topic OR randomly
OR trial OR PT clinical trial)
Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)

Appendix 2. Risk of bias tool
The following issues were evaluated and entered into the risk of bias table.
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
a. low risk (any truly random process e.g. random number table; computer random number generator);
b. high risk (any non-random process e.g. odd or even date of birth; hospital or clinic record number); or
c. unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
a. low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
b. high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
c. unclear risk.
3. Blinding (checking for possible performance bias). Was knowledge of the allocated intervention adequately prevented during the study?
At study entry? At the time of outcome assessment?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which intervention
a participant received. Blinding was assessed separately for different outcomes or classes of outcomes. We categorized the methods as:
a. low risk, high risk or unclear risk for participants;
b. low risk, high risk or unclear risk for personnel; and
c. low risk, high risk or unclear risk for outcome assessors.
4. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were incomplete
outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis.
We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion when reported and whether missing data were balanced across groups or were
related to outcomes. When sufficient information was reported or supplied by trial authors, we re-included missing data in the analyses.
We categorised the methods as:
a. low risk (< 20% missing data);
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b. high risk (≥ 20% missing data); or
c. unclear risk.
5.Selective reporting bias. Are reports of the study free of the suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We
assessed the methods as:
a. low risk (when it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review have been
reported);
b. high risk (when not all the study’s prespecified outcomes have been reported; one or more reported primary outcomes were not
prespecified outcomes of interest and were reported incompletely and so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported); or
c. unclear risk.
6. Other sources of bias. Was the study apparently free of other problems that could put it at a high risk of bias?
For each included study, we described any important concerns that we had about other possible sources of bias (e.g. whether a potential
source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We
assessed whether each study was free of other problems that could put it at risk of bias as:
a. low risk;
b. high risk; or
c. unclear risk.
If needed, we planned to explore the impact of the level of bias by undertaking sensitivity analyses.
1. Sequence generation: Was the allocation sequence adequately generated?
2. Allocation concealment: Was allocation adequately concealed?
3. Blinding of participants, personnel and outcome assessors: Was knowledge of the allocated intervention adequately prevented during
the study? At study entry? At the time of outcome assessment?
4. Incomplete outcome data: Were incomplete outcome data adequately addressed?
5. Selective outcome reporting: Are reports of the study free of the suggestion of selective outcome reporting?
6. Other sources of bias: Was the study apparently free of other problems that could put it at high risk of bias?

WHAT'S NEW

Date

Event

Description

28 January 2020

Amended

Arne Ohlsson deceased.

HISTORY
Protocol first published: Issue 3, 1998
Review first published: Issue 3, 2001

Date

Event

Description

1 August 2016

New citation required but conclusions
have not changed

One new study added; conclusions unchanged

28 April 2016

New search has been performed

This review updates the existing review, "Bronchodilators for
the prevention and treatment of chronic lung disease in preterm
infants", which was published in the Cochrane Database of Systematic Reviews (Ng 2012). New searches of the literature were
conducted in March 2016 and led to the inclusion of 1 additional
study.
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Date

Event

Description

19 April 2012

New search has been performed

This review updates the existing review, "Bronchodilators for the
prevention and treatment of chronic lung disease in preterm infants", which was published in the Cochrane Database of Systematic Reviews (Ng 2009).

19 April 2012

New citation required but conclusions
have not changed

Updated search revealed 4 trials that did not qualify for inclusion
in this review.
No changes were made to review conclusions.

11 September 2008

Amended

This review updates the existing review, "Bronchodilators for the
prevention and treatment of chronic lung disease in preterm infants", which was published in the Cochrane Database of Systematic Reviews (Ng 2006).
Updated search revealed no new trials.
No changes were made to review conclusions.
Review has been converted to new review format.

30 April 2006

New search has been performed

This review updates the existing review, "Bronchodilators for the
prevention and treatment of chronic lung disease in preterm infants", which was published in the Cochrane Library, 2003, Issue
3 (Ng 2003).
Ng 2006
An updated search conducted in April 2006 (Ng 2006) identified
no new eligible studies. Review conclusions remain unchanged:
Randomised trials provided no evidence for the use of salbutamol for prevention of chronic lung disease (CLD). We are unable
to address the question as to whether bronchodilators are useful
in the treatment of patients with CLD. Future use of salbutamol
and other bronchodilators in preterm infants should occur in the
scenario of a placebo-controlled randomised clinical trial.

7 February 2001

New citation required and conclusions
have changed

Substantive amendments were made.
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